Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910890 | 0.82 | LMNA (0.54) | PTPN1PTPRCCYP2C19ALDH1A1TDP1 | |
| SCHEMBL23582506 | 0.80 | BRS3 (0.51) | PTPN1POLBGAACYP2C19PRMT1 | |
| SCHEMBL23876180 | 0.79 | KMT2A (0.50) | PTPN1PTPRCALDH1A1TDP1KMT2A | |
| SCHEMBL3045824 | 0.79 | ALDH1A1 (0.49) | PTPN1PTPRCALDH1A1TDP1KMT2A | |
| SCHEMBL23876186 | 0.79 | NPC1 (0.49) | PTPN1PTPRCPOLBCYP2C19ALDH1A1 | |
| SCHEMBL228601 | 0.79 | NR4A2 (0.51) | PTPN1PTPRCALDH1A1TDP1MAPT | |
| SCHEMBL16312770 | 0.78 | SLC15A1 (0.49) | PTPN1PTPRCALDH1A1 | |
| SCHEMBL16312742 | 0.78 | SLC7A5 (0.56) | PTPN1PTPRCALDH1A1 | |
| SCHEMBL13313606 | 0.78 | MAOB (0.59) | CYP2C19ALDH1A1FFAR1FFAR4MAPT | |
| SCHEMBL23582738 | 0.77 | AKR1B10 (0.51) | ALDH1A1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2025-11-04 | — | — | US | disclosed |
| CN-116056706-B | Biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-27 | — | — | CN | disclosed |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-116056706-A | Novel biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022050749-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | 주식회사 엘지화학 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | PTPN1 4307/4885PTPRC 3865/4885POLB 3637/4885 |
| US-12459915-B2 | Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, LCAT | PTPN1 4096/4885PTPRC 3487/4885POLB 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.